<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Neuregulin-1 attenuates development of cardiomyopathy, atherosclerosis and nephropathy in a type 1 diabetes mouse model with high cardiovascular risk</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Leni</forename><surname>Vandekerckhove</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Laboratory of Physiopharmacology</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zarha</forename><surname>Vermeulen</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Laboratory of Physiopharmacology</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhi</forename><forename type="middle">Zhao</forename><surname>Liu</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">AG Nierengefäßphysiologie</orgName>
								<orgName type="department" key="dep2">Institut für Vegetative Physiologie</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Virchowweg 6</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sonia</forename><surname>Boimvaser</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Laboratory of Physiopharmacology</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Patzak</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">AG Nierengefäßphysiologie</orgName>
								<orgName type="department" key="dep2">Institut für Vegetative Physiologie</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Virchowweg 6</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vincent</forename><forename type="middle">Fm</forename><surname>Segers</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Laboratory of Physiopharmacology</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Gilles</forename><forename type="middle">W</forename><surname>De Keulenaer</surname></persName>
							<email>gilles.dekeulenaer@uantwerpen.be</email>
							<affiliation key="aff0">
								<orgName type="laboratory">Laboratory of Physiopharmacology</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">University of Antwerp</orgName>
								<orgName type="institution" key="instit2">CDE</orgName>
								<address>
									<addrLine>Universiteitsplein 1</addrLine>
									<postCode>T2.30, 2610</postCode>
									<settlement>Wilrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Neuregulin-1 attenuates development of cardiomyopathy, atherosclerosis and nephropathy in a type 1 diabetes mouse model with high cardiovascular risk</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4AE2769BA77FD62EAE2416FD7320FAF7</idno>
					<idno type="DOI">10.1152/AJPENDO.00432.2015</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Neuregulin-1 -Type 1 diabetes -Heart Failure -Atherosclerosis -Nephropathy</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author's contributions</head><p><s>-LV, VFMS and GWDK participated in the design of the studies, contributed to the interpretation of the results and prepared the manuscript.</s></p><p><s>-Animal experiments were performed by LV, ZV and SB.</s></p><p><s>-Cell culture experiments were executed by LV and ZV.</s></p><p><s>-Echocardiographic and hemodynamic measurements, molecular assays, histological examination and statistical data analysis were performed by LV.</s></p><p><s>-Vasoconstriction studies on glomerular arterioles were performed by ZZL and PA.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Diabetes is a world-wide health problem with high morbidity and mortality rates.</s><s>About half of the patients with diabetes die as a consequence of cardiovascular disease <ref type="bibr" target="#b31">(29)</ref>.</s><s>Although type 2 diabetes is more frequent and more intensively studied, type 1 diabetes also imparts a substantial risk for cardiovascular disease <ref type="bibr" target="#b39">(37)</ref>.</s><s>Even though insulin treatment has significantly reduced cardiovascular risk, patients with type 1 diabetes still have 2 to 5-fold more chance to develop cardiovascular disease than non-diabetic age-matched patients <ref type="bibr" target="#b33">(31)</ref>.</s><s>Another major complication of type 1 diabetes is renal failure, with 30% of type 1 diabetic patients developing kidney disease, often progressing to end-stage renal disease (ESDR) <ref type="bibr">(1)</ref>.</s><s>Importantly, the currently available treatment options have failed to sufficiently attenuate the number of patients progressing to ESRD <ref type="bibr" target="#b16">(16)</ref>.</s></p><p><s>NRG-1 is a growth factor of the epidermal growth factor family which acts through ErbB2, ErbB3 and ErbB4 tyrosine kinase receptors in a paracrine and autocrine fashion.</s><s>The NRG-1/ErbB system is indispensable during embryological development of the heart and nervous system <ref type="bibr" target="#b13">(13,</ref><ref type="bibr" target="#b19">19,</ref><ref type="bibr" target="#b29">27)</ref>.</s><s>In post-natal life, NRG-1 released by cardiac endothelial cells has cell protective, regenerative and anti-fibrotic effects in the myocardium <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b11">11)</ref>.</s><s>In animals, recombinant NRG-1 has beneficial effects on several forms of cardiomyopathy including ischemic, toxic, viral and diabetic cardiomyopathy <ref type="bibr" target="#b24">(23,</ref><ref type="bibr" target="#b28">26)</ref>.</s><s>With specific relation to diabetes, endogenous NRG-1 signaling may be impaired in type 1 diabetic cardiomyopathy, while exogenous treatment with NRG-1 has reversed cardiac remodeling in diabetic rats <ref type="bibr" target="#b14">(14,</ref><ref type="bibr" target="#b23">22,</ref><ref type="bibr" target="#b24">23,</ref><ref type="bibr" target="#b36">34)</ref>.</s><s>Currently, two forms of recombinant NRG-1 are being examined in clinical trials as potential therapies for heart failure with a reduced LV ejection fraction <ref type="bibr" target="#b12">(12,</ref><ref type="bibr" target="#b17">17)</ref>.</s><s>In addition to effects on cardiomyopathy, NRG-1 has also has arterioprotective effects by suppressing macrophage foam cell formation <ref type="bibr" target="#b47">(44)</ref>.</s><s>These effects have been observed in hypercholesterolemic ApoE-/-mice, and the molecular mechanisms involved a reduced endocytosis of acetylated low density lipoprotein and a reduced cholesterol ester formation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4</head><p><s>These effects were caused by downregulation of scavenger receptor class A and acylcoenzyme A:cholesterol acyltransferase 1, respectively, and increased Apolipoprotein A-Imediated cholesterol efflux in macrophages.</s></p><p><s>Besides regulatory effects in the cardiovascular system, NRG-1 may have a more general physiological role, as suggested by the expression of NRG-1 and ErbB receptors in the central nervous system, liver, skeletal muscle, pulmonary cells, intestine and kidney <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b35">33)</ref>.</s><s>With specific regard to the kidney, ErbB2, ErbB3 and ErbB4 are expressed in glomeruli and/or tubuli, with restricted expression of glomerular ErbB4 in mesangial cells <ref type="bibr" target="#b48">(45)</ref>.</s><s>A more profound role for the ErbB4 receptor in renal physiology has not been shown, but a potential role for the maintenance of renal structure has been suggested by the accelerated development of polycystic kidney disease in absence of this receptor <ref type="bibr" target="#b49">(46)</ref>.</s></p><p><s>Recently, genome-wide association studies (GWAS) of type 1 diabetes-associated nephropathy showed association with an intronic single nucleotide polymorphism in the ErbB4 gene <ref type="bibr" target="#b3">(4,</ref><ref type="bibr" target="#b40">38)</ref>.</s></p><p><s>Heart failure is often associated with renal dysfunction, especially in diabetes, and both diseases share risk factors and pathophysiological pathways.</s><s>For example, chronic heart failure and chronic renal dysfunction respond to treatment with angiotensin inhibitors <ref type="bibr" target="#b9">(10,</ref><ref type="bibr" target="#b15">15)</ref>.</s><s>Interestingly, recent studies show that albuminuria is associated with LV remodeling and worse outcomes of chronic heart failure <ref type="bibr" target="#b18">(18)</ref>.</s></p><p><s>In this study, we hypothesized that cardioprotective effects of NRG-1 are associated with nephroprotective effects within one disease process.</s><s>We tested this hypothesis in atherosclerosis-prone ApoE-/-type 1 diabetic mice.</s><s>As previously shown, these mice develop LV contractile dysfunction, atherosclerosis and nephropathy <ref type="bibr" target="#b43">(40,</ref><ref type="bibr" target="#b45">42)</ref>.</s><s>We show that rhNRG-1, in the absence of effects on glycemia and cholesterolemia, attenuates development of LV dysfunction, atherosclerotic plaque formation and nephropathy.</s><s>Whereas effects of rhNRG-1 on the development of LV dysfunction and atherosclerosis have been described before, protective effects on nephropathy are novel.</s><s>We further show that the mechanisms underlying NRG-1-mediated nephroprotection are different from those recruited by inhibitors of the renin-angiotensin system, and may include an inhibitory action on transforming growth factor-β1 (TGF-β1) mediated matrix production by glomerular mesangial cells.</s><s>These data reinforce the emerging therapeutic potential of NRG-1 in cardiovascular disease, and may open new avenues for therapeutic application in nephropathy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental animals and study design</head><p><s>All experiments were approved by the institutional ethics committee and conform to the Laboratory bred male ApoE-/-mice were initially obtained from Jackson Laboratories (Strain 002052).</s><s>Although mostly used in studies of vascular disease, ApoE-/-mice also develop accelerated nephropathy <ref type="bibr" target="#b45">(42)</ref>.</s><s>Diabetes type 1 was induced at the age of 16 weeks by a lowdose streptozotocin (STZ) treatment (ApoE-/-STZ mice, dose STZ 60 mg/kg, 5 consecutive days, i.p., 0.05 M Na citrate, Sigma Aldrich).</s><s>ApoE-/-STZ mice with blood glucose lower than 300 mg/dl at 2 weeks after the initial STZ injections or during further follow-up (in absence of insulin treatment) were excluded from the experiment.</s><s>Non-diabetic ApoE-/control mice were sham treated with citrate buffer and randomized to either receive (a) vehicle (vehicle-treated ApoE-/-control mice, n=12, PBS, 5 days/week, i.p.) or (b) rhNRG-1 (rhNRG-1-treated ApoE-/-control mice, n=12, recombinant human heregulin β-1, 20 µg/kg.day, 5 days/week, i.p., PeproTech) over a period of 14 weeks.</s><s>ApoE-/-STZ mice were randomized into treatment with (c) vehicle (vehicle-treated ApoE-/-STZ mice, n=21, dosing as above), (d) insulin (insulin-treated ApoE-/-STZ mice, n=22, INS, 0.3 U/kg.day,</s><s>Linshin 6 Canada), or (e) rhNRG-1β (rhNRG-1-treated ApoE-/-STZ mice, n=19, dosing as above) for 14 weeks.</s><s>Mice were weekly monitored for body weight and blood glucose (OneTouch Glucose meter).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood and urine analysis</head><p><s>24 hour urine was collected in metabolic cages at the end of the experiments, prior to sacrifice and blood collection.</s><s>Urinary albumin (Mouse albumin ELISA kit, Bethyl Laboratories) and NGAL (Neutrophil gelatinase-associated lipocalin, ab119601, Abcam) ELISA's were performed according to the manufacturer's protocol.</s><s>Urinary and serum creatinine were measured via autoanalyzer (Siemens Vista 1500) to determine creatinine clearance.</s><s>Total cholesterol levels in serum were determined via a colorimetric end-point assay (Randox Laboratories) according to the manufacturer's guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurements of LV function</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Echocardiography</head><p><s>Echocardiographic measurements were performed using a Toshiba diagnostic ultrasound system (SSA-700A), equipped with a 15 MHz transducer.</s><s>In brief, under anesthesia with sevoflurane, a 2D short-axis view of the mid-LV of mice was obtained at the chordal level.</s></p><p><s>End-systolic and end-diastolic internal dimensions (ESD and EDD, respectively) were measured on three consecutive M-mode cycles and averaged by a single observer in a blinded fashion.</s><s>Fractional shortening (FS) was calculated as %FS: ((EDD-ESD)/EDD) x 100.</s><s>Except for heart rate and %FS, measurements were normalized to individual body mass.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intra-cardiac pressure-volume measurements</head><p><s>Invasive hemodynamic measurements were recorded via cardiac catheterization.</s><s>Briefly, mice were anaesthetized with a mixture of urethane (1000 mg/kg, i.p., Sigma Aldrich), etomidate (10 mg/kg, i.p., Janssen-Cilag) and morphine (1 mg/kg, s.c., Sterop) and mechanically ventilated.</s><s>Fluid was administered via the left jugular vein.</s><s>After thoracotomy, a four-electrode pressure conductance catheter (1.4F, SPR-839, Millar Instruments) was inserted into the LV through the apex.</s><s>Steady-state measurements were recorded and LV preload decreased by occlusion of the inferior vena cava for 5-10s to derive loadindependent parameters of contractility (slope of the end-systolic pressure-volume relation (ESPVR)), parameters of ventriculo-arterial coupling (end-systolic elastance/arterial elastance, Ees/Ea) and of diastolic LV stiffness (slope of the end-diastolic pressure-volume relation (EDPVR)) (Powerlab/4SP, ADInstruments, LabChart 7 Pro Software).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histological analysis</head><p><s>The apex of the heart, the brachiocephalic artery and the left kidney were fixed in 4% All images were captured via light microscopy (Olympus U-TU1X-2, Japan), and unbiased histological quantification was performed by investigators blinded for the origin of the samples using ImageJ software.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vasoconstriction studies of the renal efferent and afferent arteriole</head><p><s>Both renal efferent and afferent arterioles were isolated from healthy male C57BL/6N mice (25-30g).</s><s>In brief, mice were sacrificed and kidneys isolated and sliced in thin transversal sections.</s><s>Next, afferent and efferent arterioles from the outer cortex with attached glomerulus were isolated.</s><s>Glass pipettes mounted in a perfusion system were used to fix and perfuse the arteriole and glomerulus.</s><s>The proximal and distal ends of the afferent and efferent arteriole, respectively, were aspirated into a holding pipette.</s><s>The inner perfusion pipette was advanced into the lumen of the arteriole.</s><s>This pipette was connected to a reservoir containing perfusion solution and to a manometer.</s><s>The arterioles were perfused at 37°C with a pressure of 100 mmHg in the pressure head for afferent arterioles and 60 mmHg for efferent arterioles.</s></p><p><s>After a 10 minute adaptation period, the afferent and efferent arterioles were treated with rhNRG-1 (n=11, 50 ng/mL, PeproTech) or with vehicle (n=12) for 20 minutes, after which rhNRG-1 remained present in the bath solution during measurements.</s><s>Thereafter, Ang II (Sigma Aldrich) concentration response curves (10 -12 mol/L to 10 -6 mol/L) with a 2 minute interval between every application were performed.</s><s>In efferent arterioles, an additional series of measurements (n=4) was performed where the AT1 receptor inhibitor ZD7155 (Tocris)</s></p><p><s>was added together with rhNRG-1 during the concentration response for Ang II.</s><s>Experiments were recorded as serial digital pictures (one per second at the last 15 to 10 seconds) by a digital camera attached to the microscope (Moticam2), and vessel diameter was measured using ImageJ.</s><s>The statistical analysis of steady-state responses was calculated from the average diameter of the 5 seconds of each interval.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal mesangial cells</head><p><s>Primary mouse (Swiss) renal glomerular mesangial cells (P10628, Innoprot, Spain) were authenticated by and cultured according to the manufacturer's protocol in DMEM, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco, ThermoFisher Scientific, Waltham).</s><s>Presence of ErbB receptors in mesangial cells was analyzed by western blotting.</s><s>In order to assess collagen synthesis, mesangial cells were stimulated with TGF-β1 (10 ng/mL, PeproTech) in the presence or absence of rhNRG-1β (50 ng/mL, PeproTech).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blotting and immunoprecipitation</head><p><s>Cardiac tissue, kidneys or mesangial cells were collected in lysis buffer suitable for western blotting or immunoprecipitation.</s><s>Antibodies used were ErbB2 (c-erbB-2 Ab-1 (21N), Neomarkers), ErbB3 (D22C5, Cell Signaling), and ErbB-4 (C-18, Santa Cruz), total eNOS (C-20, Santa Cruz), phospho eNOS (Ser1177, Cell Signaling) and GAPDH (sc-25778, Santa Cruz).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Real-Time quantitative PCR</head><p><s>Total RNA was isolated from the heart, kidneys and mesangial cells.</s><s>Using TaqMan realtime PCR (Life Technologies), TGF-β1 (Mm01178820_m1, tgfb1), procollagen 1a1 (Mm00801666_g1, Col1a1), procollagen 3a1 (Mm01254476_m1, Col3a1), myosin heavy chain α (MHCα, Mm00440359_m1, Myh6) and β (MHCβ, Mm01319006_g1, Myh7) mRNA levels were determined in the heart.</s><s>TGF-β1, procollagen 4a1 (Mm01210125_m1, Col4a1) and fibroblast specific protein-1 (FSP-1, Mm01210125_m1, s100a4) mRNA expression was analyzed in whole kidney tissue.</s><s>In mesangial cells, collagen synthesis was determined by procollagen 4a1 and fibronectin-1 (Mm01256744_m1, Fn-1) expression.</s><s>Gene expression of the gene of interest was normalized to the expression of β-actin (Mm00607939_s1, Actb)</s></p><p><s>and expressed as fold induction to control values.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis and statistics</head><p><s>Data are expressed as means ± SEM.</s><s>Differences between groups were analyzed by oneway or two-way ANOVA with Bonferroni corrections for multiple comparisons.</s><s>Data of the vasoconstriction studies were compared by using the Brunner's test.</s><s>Western blots were subjected to densitometric analysis using ImageJ 1.42 software.</s><s>Statistical significance was defined as P &lt; 0.05.</s><s>All statistical analyses were done using GraphPad Prism 6, IBM SPSS Statistics 22, and the "R" (The R-project, http://www.r-project.org)</s><s>software.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Neuregulin-1 has no effect on glycemia and plasma cholesterol levels in ApoE-/-STZ mice Vehicle-treated ApoE-/-STZ mice were hyperglycemic and hypercholesterolemic, displayed a reduced body weight despite an increased food and water intake, and an increased diuresis (Table <ref type="table" target="#tab_0">1</ref>), all signs of diabetes mellitus.</s><s>As expected, treatment of ApoE-/-STZ mice with insulin significantly attenuated or completely prevented these characteristics.</s><s>By contrast, treatment of ApoE-/-STZ mice with rhNRG-1 did not affect plasma glucose or cholesterol levels, body weight, diuresis, or food and water intake.</s><s>Also, rhNRG-1 had no effect on these parameters in ApoE-/-control mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuregulin-1 prevents diabetes-induced cardiac dysfunction in ApoE-/-STZ mice</head><p><s>Echocardiographic measurement showed that vehicle-treated ApoE-/-STZ mice develop LV dilatation, as shown by the significant increase in EDD (Table <ref type="table">2</ref>, representative images in Fig. <ref type="figure" target="#fig_4">1A</ref>).</s><s>These mice also develop severe LV contractile dysfunction, as shown by the 11 marked decrease in the slope of ESPVR and in Ees/Ea (Table <ref type="table">3</ref>, representative images in Fig. <ref type="figure" target="#fig_4">1B</ref>).</s><s>LV fractional shortening (%FS), a load-dependent parameter of global pump performance, remained unchanged.</s><s>The slope of EDPVR, a parameter of diastolic LV stiffness showed a trend to be reduced in the vehicle-treated ApoE-/-STZ mice (p= 0.11), consistent with reduced overall chamber stiffness in this model, as previously described <ref type="bibr" target="#b27">(25)</ref>.</s></p><p><s>As further shown in Table <ref type="table">2 and 3</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuregulin-1 inhibits the development of diabetic nephropathy in ApoE-/-STZ mice</head><p><s>As shown in figure <ref type="figure" target="#fig_6">3A</ref>, histological analysis showed that ErbB2 and ErbB4 were abundantly present in glomerular cells and in tubular epithelial cells, whereas expression of ErbB3 was nearly absent.</s><s>Systemic administration of rhNRG-1 by intraperitoneal injection induced phosphorylation of ErbB2 and ErbB4 receptors in peripheral organs, including the heart and kidneys (Fig. <ref type="figure" target="#fig_6">3B</ref>).</s><s>Histological analysis revealed marked glomerulosclerosis (Fig. <ref type="figure" target="#fig_6">3D</ref>, a significant nearly 4-fold increase of fibrotic area within the glomerular tuft area versus vehicle-treated ApoE-/-control mice) and a trend to a decrease in podocyte positivity (p=0.083</s><s>versus vehicle-treated ApoE-/-control mice, data not shown) in vehicle-treated ApoE-/-STZ mice.</s><s>Mesangial matrix expansion, hypercellularity, glomerular basement membrane thickening and apoptosis (data not shown), which are signs of nephropathy described in some, but not all diabetic models, were not detected.</s><s>Glomerulosclerosis (Fig. <ref type="figure" target="#fig_6">3D</ref>), but not podocyte loss, was significantly prevented by insulin treatment.</s><s>Strikingly, also rhNRG-1 significantly attenuated glomerulosclerosis, to the same extent as insulin (Fig. <ref type="figure" target="#fig_6">3D</ref>).</s><s>In addition, rhNRG-1 prevented the upregulation of FSP-1 and Col4a1 mRNA expression in renal tissue (Fig. <ref type="figure" target="#fig_6">3E</ref>), which is consistent with anti-fibrotic effects of rhNRG-1 in the diabetic kidney.</s><s>Expression of TGF-β1 (Fig. <ref type="figure" target="#fig_6">3E</ref>), a mediator of glomerular fibrosis which was only slightly upregulated in vehicletreated ApoE-/-STZ mice, remained unaffected by both insulin and rhNRG-1 treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuregulin-1 does not affect Ang II-induced vasocontriction of glomerular arterioles</head><p><s>Development of diabetic nephropathy is linked to increased renal activity of Ang II, vasoconstriction of glomerular efferent arterioles and increased glomerular filtration pressure <ref type="bibr" target="#b30">(28)</ref>.</s><s>Figure <ref type="figure">4A</ref> shows that rhNRG-1, in contrast to the selective angiotensin type 1A receptor antagonist ZD7155, did not inhibit Ang II-induced vasoconstriction of glomerular arterioles.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuregulin-1 inhibits TGF-β1-induced fibrotic responses of glomerular cells in vitro</head><p><s>Cultured mesangial cells are the main source of extracellular matrix in the glomerulus.</s><s>In view of the observation that rhNRG-1 reduced glomerular fibrosis, we studied the direct effects of rhNRG-1 on mesangial cells.</s><s>Figure <ref type="figure">4C</ref> shows expression of ErbB2 and ErbB4 receptors in these cells.</s><s>Figure <ref type="figure">4D</ref> shows that treatment of mesangial cells with rhNRG-1 robustly attenuated TGF-β1-induced upregulation of Fn-1 and Col4a1 mRNA synthesis, implying a direct inhibitory effect of rhNRG-1 on mesangial cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This study demonstrates preventive therapeutic effects of rhNRG-1 in different organs of hypercholesterolemic diabetic mice, prone to development of dilated cardiomyopathy, atherosclerosis and nephropathy.</s><s>Although beneficial effects on the failing heart and on atherosclerosis have been described before, effects of rhNRG-1 on glomerulosclerosis and nephropathy are entirely novel.</s><s>The NRG-1/ErbB system is a cell growth and cell differentiation promoting system with a remarkable diversity of functions throughout life.</s></p><p><s>During embryogenesis, this system is indispensable for several processes including development of the heart, mammary tissue and the nervous system, participating in ventricular trabeculation, cardiac valve formation and axonal myelination by Schwann cells <ref type="bibr" target="#b29">(27)</ref>.</s><s>In postnatal/adult life, the NRG-1/ErbB system is expressed in many tissues <ref type="bibr" target="#b4">(5)</ref>.</s></p><p><s>Regulatory effects have been shown in the brain cardiovascular control system, skeletal muscle, neurons, atherosclerotic vessel wall, myocardium etc. <ref type="bibr" target="#b20">(20,</ref><ref type="bibr" target="#b35">33)</ref>.</s><s>In this study, we confirmed that rhNRG-1 suppresses the formation of atherosclerotic lesions in ApoEdeficient mice <ref type="bibr" target="#b47">(44)</ref>.</s></p><p><s>We also confirmed that rhNRG-1 attenuates the development of LV dilatation and of LV contractile dysfunction in type 1 diabetes.</s><s>The protective characteristics of rhNRG-1 against LV dilatation have already been described in several models of cardiomyopathy and heart failure <ref type="bibr" target="#b28">(26)</ref>.</s><s>The precise mechanisms underlying the cardioprotective effects of NRG-1/ErbB signaling in vivo, however, are still incompletely understood, and may be circumstancedependent.</s><s>Upon acute myocardial injury, NRG-1 may desensitize the myocardium for adrenergic stimulation and increase cardiomyocyte threshold for apoptosis and ischemic cell death <ref type="bibr" target="#b21">(21)</ref>.</s><s>In a chronic stabilized condition, NRG-1 may induce cardiomyocyte mitosis and promote myocardial regeneration <ref type="bibr" target="#b2">(3)</ref>.</s><s>Also, protection against diabetic cardiomyopathy in type 1 diabetes has been described <ref type="bibr" target="#b23">(22,</ref><ref type="bibr" target="#b24">23)</ref>.</s><s>Consistent with previous data, rhNRG-1</s></p><formula xml:id="formula_0">15</formula><p><s>reversed cardiac MHC-α downregulation and enhanced LV eNOS phosphorylation, presumably contributing to improved contractile function and reduced LV remodeling <ref type="bibr" target="#b23">(22,</ref><ref type="bibr" target="#b25">24)</ref>.</s></p><p><s>Interestingly, in this study, the beneficial effects of rhNRG-1 on LV remodeling and dysfunction in diabetes occurred in the absence of increased myocardial fibrosis (which was consistent with the reduced LV stiffness in vehicle-treated ApoE-/-STZ mice) and apoptosis, implicating fibrosis-and apoptosis-independent protective pathways.</s><s>These observations may be different from previous studies with rhNRG-1 in diabetic models <ref type="bibr" target="#b23">(22,</ref><ref type="bibr" target="#b24">23)</ref>.</s><s>In this study, absence of increased myocardial fibrosis was confirmed by 3 immunohistological staining methods and by mRNA analysis of fibrotic markers.</s><s>Although various studies have shown myocardial fibrosis and apoptosis in different models of diabetic cardiomyopathy, other investigators have observed absence of fibrosis and apoptosis <ref type="bibr" target="#b34">(32)</ref>.</s><s>Variability in the degree of myocardial fibrosis and apoptosis in diabetic rodent models has been explained by differences in animal species (2), differences in mouse strains <ref type="bibr" target="#b44">(41)</ref>, variable levels of hyperglycemia <ref type="bibr" target="#b42">(39)</ref>, differences in compensatory upregulations of metalloproteinases <ref type="bibr" target="#b46">(43)</ref> and differences in the effects of STZ <ref type="bibr" target="#b6">(7)</ref>, the latter which may cause non-specific toxicity beside pancreatic injury and includes tissue apoptosis.</s><s>Importantly, in our study, all cardiac changes in ApoE-/-STZ mice were prevented by insulin, supporting that hyperglycemia, rather than non-specific STZ toxicity was the responsible factor.</s></p><p><s>The most important and novel finding of this study was the protective effect of rhNRG-1 on the development of diabetic nephropathy.</s><s>More specifically, we found that rhNRG-1 attenuated albuminuria and NGALuria, respective biomarkers of glomerular and tubular injury, and protected against histological glomerulosclerosis.</s><s>Glomerulosclerosis is a complex process induced by a dysregulated metabolic milieu (including hyperlipidemia and hyperglycemia) and is characterized by a combination of factors including glomerular basement membrane thickening, endothelial dysfunction, podocyte loss, mesangial expansion and accumulation of extracellular matrix <ref type="bibr" target="#b37">(35)</ref>.</s><s>Some, but not all, of these characteristics were present in our model, suggesting that the level of nephropathy was rather mild.</s><s>Strikingly, accumulation of glomerular matrix in ApoE-/-STZ mice was completely prevented by rhNRG-1, to the same extent as insulin.</s><s>Accumulation of glomerular matrix is a final common pathway during glomerulosclerosis, resulting from the activation of mesangial cells by TGF-β1 <ref type="bibr" target="#b50">(47)</ref>.</s><s>An inhibitory effect of rhNRG-1 on matrix formation was recapitulated on cultured mesangial cells in vitro.</s><s>Direct inhibition of mesangial cells may thus contribute to the nephroprotective effects of rhNRG-1 in ApoE-/-STZ mice.</s><s>We do not exclude, however, that other direct actions of rhNRG-1 on renal tissue contribute, or that indirect effects, coupled to the attenuation of atherosclerosis and/or LV dysfunction, play a role.</s></p><p><s>Despite the introduction of renoprotective therapy, mostly consisting of inhibitors of the reninangiotensin system, the incidence of diabetic kidney disease is increasing, and the prognosis of albuminuria remains poor, frequently progressing to ESRD <ref type="bibr" target="#b16">(16)</ref>.</s><s>Therefore, the current observation of renoprotective effects of rhNRG-1, a protein already introduced in clinical trials with concomitant protective effects on atherosclerosis and heart failure, is a fascinating discovery with translational potential.</s><s>Interestingly, studies in isolated glomerular arterioles showed that rhNRG-1 did not inhibit Ang II-induced vasoconstriction.</s><s>These observations indicate that the protective mechanisms of rhNRG-1 on nephropathy differ from those of inhibitors of the renin-angiotensin system, in the sense that at least the renal hemodynamic component of rhNRG-1 is clearly different.</s></p><p><s>This study, together with the recent GWAS in diabetic nephropathy, should encourage further studies on the function of NRG-1/ErbB system in the kidney, and on the potential therapeutic application of rhNRG-1 in diabetic nephropathy <ref type="bibr" target="#b3">(4,</ref><ref type="bibr" target="#b40">38)</ref>.</s><s>This study uncovers renoprotective of rhNRG-1, preventively administrated in a model of rather mild nephropathy from onset of type 1 diabetes, hence before initiation of renal disease.</s><s>Obviously, it would be interesting to confirm these observations in more severe and standardized models of diabetic nephropathy that more utterly recapitulate the features of human diabetic nephropathy, and to initiate therapy after onset of renal disease, e.g.</s><s>upon detection of albuminuria, a regimen which may be more clinically relevant <ref type="bibr" target="#b5">(6)</ref>.</s></p><p><s>In conclusion, in a diabetes type 1 mouse model with a high cardiovascular risk, this proof of concept study shows that systemic delivery of rhNRG-1 exerts a combined cardioprotective, anti-atherosclerotic and nephroprotective effect, in the absence of effects on blood glucose or cholesterol levels.</s><s>In particular, this study uncovers that rhNRG-1 may protect against nephropathy, occurring by mechanistic pathways that at least partly diverge from reninangiotensin inhibitors, and potentially involve direct inhibitory actions on renal mesangial cells.</s><s>Based on these data, the nephroprotective effects of rhNRG-1 should be further explored as a potential novel therapeutic avenue for kidney disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure captions</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>buffered formalin and embedded in paraffin.</s><s>Sections of the heart were stained with Sirius red, Masson's trichrome and TUNEL (Terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate (dUTP) nick-end labeling) according to the manufacturer's instructions or with an antibody specific for collagen type III (T3330G, Campro Scientific) to determine cardiac fibrosis and apoptosis.</s><s>Staining of the arteria brachiocephalica includes hematoxylin &amp; eosin (H&amp;E) for the determination of atherosclerotic plaques and the necrotic core, immunostaining for mac-3 (M3/84, Santa Cruz) in order to quantify the number of macrophages and TUNEL for apoptosis analysis.</s><s>Quantification of positive staining was normalized to plaque surface.</s><s>Sections of the kidneys were stained with periodic acid shiffbase (PAS), Masson's trichrome and TUNEL according to the manufacturer's protocol or with the podocyte specific antibody WT-1 (Wilm's Tumor-1, ab89901, Abcam), in order to and podocyte expression.</s><s>Per kidney, 20 images of outer cortical glomerular cross-sections where analyzed as previously described<ref type="bibr" target="#b38">(36)</ref>.</s><s>Glomerular positivity was expressed as the ratio of the percentage of positive staining to the glomerular tuft area.</s><s>Presence of the NRG-1 specific receptors, ErbB2 to ErbB4 (c-erbB-2 Ab-1 (21N), Neomarkers, HER3/ErbB3, D22C5, Cell Signaling, and ErbB-4 (C-18), Santa Cruz, respectively), within the kidney were determined by immunohistological staining.</s><s>Negative controls were performed with secondary antibody only.</s><s>Sections of a mouse thymus were used as a positive control for the TUNEL staining.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>12 Neuregulin- 1</head><label>121</label><figDesc><div><p><s>figure 2, analyses of the arteria brachiocephalica revealed dense plaque formation in vehicle-treated ApoE-/-STZ mice.</s><s>Insulin significantly reduced plaque formation in ApoE-/-</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure</head><label></label><figDesc><div><p><s>Figure3Cshows protective effects of insulin and rhNRG-1 on the development of</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: Representative images of echocardiographic and hemodynamic</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: Effect of NRG-1 on atherosclerotic plaque formation.</s><s>(A) Representative</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Presence and activation of ErbB receptors and the effect of NRG-1 on</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head></head><label></label><figDesc><div><p><s>Figure 1 A B</s></p></div></figDesc><graphic coords="28,267.73,81.81,212.60,138.91" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="31,344.65,86.72,184.30,275.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Physiological parameters</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>ApoE-/-control</cell><cell>ApoE-/-control</cell><cell>ApoE-/-STZ</cell><cell>ApoE-/-STZ</cell><cell>ApoE-/-STZ</cell></row><row><cell></cell><cell>+ vehicle</cell><cell>+ NRG-1</cell><cell>+ vehicle</cell><cell>+ INS</cell><cell>+ NRG-1</cell></row><row><cell></cell><cell>(n=12)</cell><cell>(n=12)</cell><cell>(n=12)</cell><cell>(n=12)</cell><cell>(n=12)</cell></row><row><cell>Body</cell><cell>31.6 ± 1.5</cell><cell>31.8 ± 2.3</cell><cell>25.8 ± 2.8</cell><cell>28.1 ± 3.8</cell><cell>26.7 ± 3.7</cell></row><row><cell>weight (g)</cell><cell></cell><cell></cell><cell>***</cell><cell>†</cell><cell>**</cell></row><row><cell>Glycemia</cell><cell>205 ± 32</cell><cell>178 ± 11</cell><cell>554 ± 46</cell><cell>194 ± 69</cell><cell>536 ± 72</cell></row><row><cell>(mg/dL)</cell><cell></cell><cell></cell><cell>***</cell><cell>† † †</cell><cell>***</cell></row><row><cell>Cholesterol</cell><cell>265 ± 42</cell><cell>203 ± 10</cell><cell>459 ± 58</cell><cell>294 ± 18</cell><cell>366 ± 48</cell></row><row><cell>(mg/dL)</cell><cell></cell><cell></cell><cell>*</cell><cell>†</cell><cell></cell></row><row><cell>Food</cell><cell>3.0 ± 0.46</cell><cell>3.4 ± 1.0</cell><cell>4.7 ± 1.2</cell><cell>3.3 ± 1.0</cell><cell>4.0 ± 1.4</cell></row><row><cell>intake (g)</cell><cell></cell><cell></cell><cell>***</cell><cell>† † †</cell><cell>*</cell></row><row><cell>Water</cell><cell>3.6 ± 1.4</cell><cell>3.40 ± 1.7</cell><cell>18.6 ± 8.2</cell><cell>6.10 ± 3.5</cell><cell>14.4 ± 9.2</cell></row><row><cell>intake (mL)</cell><cell></cell><cell></cell><cell>***</cell><cell>† † †</cell><cell>***</cell></row><row><cell>Urine</cell><cell>1.20 ± 0.37</cell><cell>1.10 ± 0.53</cell><cell>15.1 ± 7.6</cell><cell>2.20 ± 2.2</cell><cell>11.5 ± 8.1</cell></row><row><cell>(mL/24h)</cell><cell></cell><cell></cell><cell>***</cell><cell>† † †</cell><cell>***</cell></row></table><note><p><s>Values represent mean ± SEM.NRG-1, Neuregulin-1; STZ, Streptozotocin; INS, Insulin.</s><s>*Versus ApoE-/-control + vehicle, *p&lt;0.05,</s><s>**p&lt;0.01,</s><s>***p&lt;0.001.</s><s>†Versus ApoE-/-STZ + vehicle, †p&lt;0.05,</s><s>† † †p&lt;0.001.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We would like to thank Katrien Demol and Rita Van Den Bossche for excellent technical support.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Grants</head><p><s>This work was supported by a research grant from the "Fonds voor Wetenschappelijk Onderzoek" Vlaanderen (Application number, G0C5214), by a grant from the European Commission (FP7-HEALTH-F2-2010-261409), by an IOF POC of the University of Antwerp, project #FFI150002, by a DeHousse mandaat of the University of Antwerp (ZV) and by an Amidila Postdoctoral fellowship from Erasmus Mundus (SB).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosures</head><p><s>The authors declare that they have no competing interests, financial or otherwise.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A p o E -/ -c o n t r o l + v e h i c l e A p o E -/ -c o n t r o l + N R G -1 A p o E -/ -S T Z + v e h i c l e A p o E -/ -S T Z + I N S A p o E -/ -S T Z + N R G</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The epidemiology of chronic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Atkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int Suppl</title>
		<imprint>
			<biblScope unit="page" from="S14" to="S18" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse</title>
		<author>
			<persName><forename type="first">I</forename><surname>Banerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Fuseler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Borg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Baudino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Heart Circ Physiol</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page" from="H1883" to="H1891" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bersell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Haring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kuhn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="257" to="270" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">GWAS of diabetic nephropathy: is the GENIE out of the bottle?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Boger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Sedor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Genet</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e1002989</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The neuregulin-I/ErbB signaling system in development and disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Britsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Anat Embryol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page" from="1" to="65" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Mouse models of diabetic nephropathy</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Brosius</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Alpers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Bottinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Breyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Coffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gurley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kakoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kretzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Leiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Mcindoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Smithies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Susztak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2503" to="2512" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Deeds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Gastineau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Hiddinga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jahangir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Kudva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Anim</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="131" to="140" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Diabetes mellitus induces changes in cardiac myosin of the rat</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Dillmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="579" to="582" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Neuregulin 1 Improves Glucose Tolerance in db/db Mice</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ennequin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Boisseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Caillaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chavanelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Etienne</forename><forename type="middle">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sirvent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0130568</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure</title>
		<author>
			<persName><forename type="first">L</forename><surname>Erhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ilgenfritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gelperin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blumenthal</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Fosinopril Efficacy/Safety Trial (FEST) Study Group</title>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1892" to="1899" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Antiremodeling and anti-fibrotic effects of the neuregulin-1beta glial growth factor 2 in a large animal model of heart failure</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Galindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kasasbeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ryzhov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lenihan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nunnally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Adcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Harrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Parry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Iaci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ganguly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Feoktistov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Stephenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Caggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sawyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cleator</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e000773</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1907" to="1914" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Casagranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Orioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lemke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="390" to="394" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Long</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Pathol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="414" to="420" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Heeg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Van Der Hem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="272" to="279" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">New therapies for diabetic kidney disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Himmelfarb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Tuttle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="2549" to="2550" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Hayward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Keogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kotlyar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mccrohon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>England</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Amor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Macdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="83" to="92" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Beussink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="586" to="596" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Requirement for neuregulin receptor erbB2 in neural and cardiac development</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hauser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="394" to="398" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lemmens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Doggen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Keulenaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="954" to="960" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Lemmens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">F</forename><surname>Segers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Demolder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Keulenaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Role of neuregulin</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">ErbB2 signaling in endothelium-cardiomyocyte cross-talk</title>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page" from="19469" to="19477" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats</title>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Ther Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1105" to="1112" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats</title>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao</forename><forename type="middle">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">69</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Effects of recombined human neuregulin on the contractibility of cardiac muscles of rhesus monkeys with pacing</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>induced heart failure</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Sichuan Da Xue Xue Bao Yi Xue Ban</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="105" to="108" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Litwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Raya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Daugherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="481" to="488" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy</title>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">J</forename><surname>Xi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1438" to="1447" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Multiple essential functions of neuregulin in development</title>
		<author>
			<persName><forename type="first">D</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Birchmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="386" to="390" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mezzano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Droguett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Burgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Ardiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Flores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Aros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Caorsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Vio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruiz-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Egido</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl S64-S70</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Morrish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Keen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Myosin heavy chain gene expression in human heart failure</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Minobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Bristow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Leinwand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2362" to="2370" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Cleary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Backlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Genuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lachin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Orchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="2643" to="2653" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Candy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Woodiwiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1905" to="1912" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Neuregulin in cardiovascular development and disease</title>
		<author>
			<persName><forename type="first">O</forename><surname>Odiete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sawyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="1376" to="1385" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1beta/ErbB in response to myocardial infarction resulting in worsening heart failure</title>
		<author>
			<persName><forename type="first">O</forename><surname>Odiete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Konik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sawyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Hill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pennathur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kretzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Brosius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iii</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1439" to="1445" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Quantification of renal pathology by image analysis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Rangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Tesch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrology (Carlton )</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="553" to="558" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Type 1 diabetes, hyperglycaemia, and the heart</title>
		<author>
			<persName><forename type="first">R</forename><surname>Retnakaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1790" to="1799" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">N</forename><surname>Sandholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Salem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mcknight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Forsblom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Isakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Mckay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Sadlier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Makinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Boright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ahlqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Deshmukh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ahola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fagerholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gordin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Harjutsalo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Heikkila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hietala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kyto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lahermo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lithovius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Osterholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Parkkonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pitkaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosengard-Barlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saraheimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Soderlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soro-Paavonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Syreeni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Thorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tikkanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tolonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tryggvason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tuomilehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Gill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prior</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guiducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Mirel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Hosseini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Parving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rossing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tarnow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ladenvall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alhenc-Gelas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lefebvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rigalleau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Tregouet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maestroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maestroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Falhammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mollsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cimponeriu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ioana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Serafinceanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stavarachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kretzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Colhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Panduru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brismar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zerbini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hadjadj</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">21</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">New susceptibility loci associated with kidney disease in type 1 diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Marre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Groop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lajer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Bull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Waggott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Hirschhorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Godson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Florez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Groop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Maxwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Genet</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e1002921</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Khode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="3297" to="3306" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Vasquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Peotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Gava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Meyrelles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biomed Sci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">22</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The role of mouse strain differences in the susceptibility to fibrosis: a systematic review</title>
		<author>
			<persName><forename type="first">L</forename><surname>Walkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Brenchley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Korstanje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Margetts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Fibrogenesis Tissue Repair</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Renal injury in apolipoprotein E-deficient mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Segerer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dantas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Hudkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Goodpaster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Leboeuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Alpers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="999" to="1006" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism</title>
		<author>
			<persName><forename type="first">D</forename><surname>Westermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rutschow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linderer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Riad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Unger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Schultheiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pauschinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tschope</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="641" to="646" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Iso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sakai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nagashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hirano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="500" to="510" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Cell Res</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="602" to="610" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Deletion of ErbB4 accelerates polycystic kidney disease progression in cpk mice</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Kloepfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="538" to="547" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">N</forename><surname>Ziyadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="631" to="638" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title level="m" type="main">Representative images and quantification of the renal glomerular fibrotic area. (E) Bar graphs showing mRNA expression in whole kidney tissue of TGF-β1, FSP-1 and Col 4a1, expressed as fold induction to ApoE-/-control + vehicle mice</title>
		<imprint/>
	</monogr>
	<note>NRG-1, Neuregulin-1</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Streptozotocin; INS, Insulin; FSP-1, Fibroblast Specific Protein</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
	<note>STZ</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Col 4a1</title>
	</analytic>
	<monogr>
		<title level="m">Procollagen 4a1</title>
				<meeting>ollagen 4a1</meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title level="m" type="main">Transforming Growth Factor-β1</title>
		<author>
			<persName><surname>Tgf-Β1</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Figure 4: Direct effect of NRG-1 on glomerular arterioles and renal glomerular mesangial cells. (A) Graphs showing the effect of Ang II on vasoconstriction in glomerular arterioles in the absence and the presence of rhNRG-1. The selective angiotensin type 1A receptor antagonist ZD7155 served as a positive control for inhibition of Ang II-induced vasoconstriction. (B) Digital microscopic images of a mouse efferent arteriole. The free end of the arteriole is aspirated into a pipette, visible on the left hand side. A. the basal situation of efferent arteriole. B. The application of NRG-1 (50ng/ml) + Ang</title>
	</analytic>
	<monogr>
		<title level="m">Urinary albumin excretion; NGAL, Neutrophil gelatinase-associated lipocalin. *versus ApoE-/-STZ + vehicle, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001</title>
				<imprint/>
		<respStmt>
			<orgName>UAE</orgName>
		</respStmt>
	</monogr>
	<note>II (10 -12 mol/l to 10 -6 mol/l</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Western blot analysis confirming the presence of ErbB2 and ErbB4 receptors in mesangial cells. (D) Bar graphs showing TGF-β1-induced mRNA expression of Fn-1 and Col4a1 in the absence and the presence of rhNRG-1 as fold induction to control</title>
	</analytic>
	<monogr>
		<title level="m">Angiotensin II; TGF-β1, Transforming Growth Factor-β1</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title/>
		<author>
			<persName><surname>Nrg-1</surname></persName>
		</author>
		<imprint>
			<pubPlace>Neuregulin-1</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title/>
		<author>
			<persName><surname>Fn-1</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m">Fibronectin-1; Col4a1; Procollagen 4a1. *versus ApoE-/-STZ + vehicle, *p&lt;0.05, **p&lt;0</title>
				<imprint>
			<biblScope unit="page">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
